Fig. 2From: A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomasProgression-Free Survival of subjects who had previously received doxorubicin compared with the entire study population. A Kaplan–Meier curve indicating the PFS of the 11 subjects who had previously received doxorubicin compared with the PFS of the total population of subjectsBack to article page